Bioavailability of betamethasone dipropionate when combined with calcipotriol

International Journal of Dermatology

Volumn 43, Issue 8, 2004, Pages 611-617

  Traulsen, Jette ^a  

^a LEO PHARMA A S   (Denmark)

Author keywords

[No Author keywords available]

Indexed keywords

BETAMETHASONE DIPROPIONATE; BETAMETHASONE DIPROPIONATE PLUS CALCIPOTRIOL; CALCIPOTRIOL; CORTICOSTEROID;

ADULT; AREA UNDER THE CURVE; ARTICLE; BIOASSAY; BIOEQUIVALENCE; CLINICAL ARTICLE; CONTROLLED STUDY; DATA ANALYSIS; DOSE TIME EFFECT RELATION; DRUG ACTIVITY; DRUG BIOAVAILABILITY; DRUG EFFICACY; DRUG FORMULATION; FEMALE; HUMAN; MALE; MEASUREMENT; OINTMENT; PSORIASIS VULGARIS; SKIN; VASOCONSTRICTION;

ADOLESCENT; ADULT; ANTI-INFLAMMATORY AGENTS; BETAMETHASONE; BIOLOGICAL AVAILABILITY; CALCITRIOL; DERMATOLOGIC AGENTS; DRUG COMBINATIONS; DRUG INTERACTIONS; HUMANS; MALE; MIDDLE AGED; PILOT PROJECTS; PSORIASIS;

EID: 4444328525     PISSN: 00119059     EISSN: None     Source Type: Journal    
DOI: 10.1111/j.1365-4632.2004.01922.x     Document Type: Article

References (20)

1. Kragballe K, Gjertsen BT, De Hoop D, et al. Double-blind, right/left comparison of calcipotriol and betamethasone valerate in treatment of psoriasis vulgaris. Lancet 1991; 337: 193-196.
2. Dubertret L, Wallach D, Souteyrand P, et al. Efficacy and safety of calcipotriol (MC 903) ointment in psoriasis vulgaris. A randomized, double-blind, right/left comparative, vehicle-controlled study. J Am Acad Dermatol 1992; 27: 983-988.
3. Ashcroft DM, Po AL, Williams HC, et al. Systematic review of comparative efficacy and tolerability of calcipotriol in treating chronic plaque psoriasis. BMJ 2000; 320: 963-967.
4. Cunliffe WJ, Berth-Jones J, Claudy A, et al. Comparative study of calcipotriol (MC 903) ointment and betamethasone 17-valerate ointment in patients with psoriasis vulgaris. J Am Acad Dermatol 1992; 26: 736-743.
5. Bruce S, Epinette WW, Funicella T, et al. Comparative study of calcipotriene (MC 903) ointment and fluocinonide ointment in the treatment of psoriasis. J Am Acad Dermatol 1994; 31: 755-759.
6. Lange K, Kleuser B, Gysler A, et al. Cutaneus inflammation and proliferation in vitro: differential, effects and mode of action of topical glucocorticoids. Skin Pharmacol Appl Skin Physiol 2000; 13: 93-103.
7. Jensen AM, Llado MB, Skov FL, et al. Calcipotriol inhibits the proliferation of hyperproliferative CD29 positive keratinocytes in psoriatic epidermis in the absence of an effect on the function and number of antigen-presenting cells. Br J Dermatol 1998; 139: 984-991.
8. Reichrath J, Muller SM, Kerber A, et al. Biological effects of topical calcipotriol (MC 903) treatment in psoriatic skin. J Am Acad Dermatol 1997; 36: 19-28.
9. van der Vleuten CJ, Snijders CG, de Jong EM, et al. Effects of calcipotriol and clobetasol-17-propionate on UVB-irradiated human skin: an immunohistochemical study. Skin Pharmacol 1996; 9: 355-365.
10. Glade CP, von Erp PEJ, Boezeman JBM, et al. Multiparameter flow cytometry as a tool to evaluate antipsoriatic therapy. Br J Dermatol 1997; 137: 367-375.
11. Lebwohl M, Siskin SB, Epinette W, et al. A multicenter trial of calcipotriene ointment and halobetasol ointment compared with either agent alone for the treatment of psoriasis. J Am Acad Dermatol 1996; 35: 268-269.
12. Ruzicka T, Lorenz B. Comparison of calcipotriol monotherapy and a combination of calcipotriol and betamethasone valerate after 2 weeks' treatment with calcipotriol in the topical therapy of psoriasis vulgaris: a multicentre, double-blind, randomized study. Br J Dermatol 1998; 138: 254-258.
13. Kragballe K, Barnes L, Hamberg KJ, et al. Calcipotriol cream with or without concurrent topical corticosteroid in psoriasis: tolerability and efficacy. Br J Dermatol 1998; 139: 649-654.
14. Ortonne JP. Psoriasis: New treatment modality with calcipotriol and betamethasone diproprionate. Nouw Dermatol 1994; 13: 746-751.
15. FDA Guidance. Topical dermatological corticosteroids: in vivo bioequivalence. Division of bioequivalence, Office of generic drugs, Rockville, MD: Food and Drug Administration, 1995.
16. Locke CS. An exact confidence interval from untranslated data for the ratio of two formulation means. J Pharmacokinet Biopharm 1984; 12: 649-655.
17. Guenther L, Cambazard F, van de Kerkhof PCM, et al. Efficacy and safety of a new combination of calcipotriol and betamethasone dipropionate (once or twice daily) compared to calcipotriol (twice daily) in the treatment of psoriasis vulgaris: a randomized, double-blind, vehicle-controlled clinical trial. Br J Dermatol 2002; 147: 316-323.
18. Papp KA, Guenther L, Boyden B, et al. Early onset of action and efficacy of a combination of calcipotriene and betamethasone dipropionate in the treatment of psoriasis. J Am Acad Dermatol 2003; 48: 48-54.
19. Douglas WS, Poulin Y, Decroix J, et al. A new calcipotriol/betamethasone formulation with rapid onset of action was superior to monotherapy with betamethasone dipropionate or calcipotriol in psoriasis vulgaris. Acta Derm Venereol 2002;82:131-135.
20. Kaufmann R, Bibby AJ, Bissonnette R, et al. A new calcipotriol/betamethasone dipropionate formulation (Daivobet™) is an effective once-daily treatment for psoriasis vulgaris. Dermatology 2002; 205: 389-393.